Research map: Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial

Back to the article

Papers in this map

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials · Richard G B Langley · 2014 · 2005 citations · Cited by this paper
  2. Lipid-based nanocarrier-enabled combination therapy for breast cancer: overcoming drug resistance toward precision oncology · 2026 · Related
  3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis · Kenneth B. Gordon · 2016 · 857 citations · Cited by this paper
  4. Apoptosis-inducing potential of tilorone dihydrochloride in triple-negative breast cancer: in silico and in vitro evidences · 2026 · Related
  5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial · Kristian Reich · 2017 · 767 citations · Cited by this paper
  6. EPA-loaded silica nanoemulsions attenuate DEN-induced hepatic fibroinflammation by modulating homocysteine, PKCα/NF-κB, and Nrf2 signaling · 2026 · Related
  7. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis · Kim Alexander Papp · 2016 · 469 citations · Cited by this paper
  8. Cycloastragenol overcomes trastuzumab resistance in HER2-positive breast cancer by regulating cell cycle and epithelial-mesenchymal transition through EZH2/PTEN/AKT pathway · 2026 · Related
  9. Signaling pathways and targeted therapies for psoriasis · Jia Guo · 2023 · 424 citations · Cited by this paper
  10. Exploring betanin regulatory impact on TGF-β and PI3K/AKT pathways in oral cancer · 2026 · Related
  11. The Immunology of Psoriasis—Current Concepts in Pathogenesis · Izabela Siemińska · 2024 · 328 citations · Cited by this paper
  12. Myrtenol modulates TWEAK/TLR4–NF-κB, miR-21, PTEN, and ERK-1 expressions and improves behavioral outcomes in a rat glioblastoma model · 2026 · Related
  13. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial · Kenneth B. Gordon · 2021 · 295 citations · Cited by this paper
  14. Protective effects of ginseng against reproductive injury: mechanisms and research progress · 2026 · Related
  15. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis · Andrew Blauvelt · 2020 · 223 citations · Cited by this paper
  16. Development of citrinin-loaded liposomes and in vitro toxicogenetic evaluation on breast cells · 2026 · Related
  17. Psoriasis · April Wang Armstrong · 2025 · 187 citations · Cited by this paper
  18. Luteolin alleviates inflammation by inhibiting the PI3K-Akt-FOXO3a pathway · 2026 · Related
  19. Advances in psoriasis research: From pathogenesis to therapeutics · Dineshwar Sugumaran · 2024 · 92 citations · Cited by this paper
  20. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies · Nicolò Costantino Brembilla · 2023 · 91 citations · Cited by this paper
  21. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! · Helen Kitchen · 2015 · 74 citations · Cited by this paper
  22. Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders · Anushka Saran · 2025 · 55 citations · Cited by this paper
  23. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials · Richard G B Langley · 2022 · 53 citations · Cited by this paper
  24. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial · Bruce E Strober · 2023 · 44 citations · Cited by this paper
  25. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial · L. Puig · 2021 · 43 citations · Cited by this paper
  26. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis · Chunlei Zhang · 2022 · 37 citations · Cited by this paper
  27. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States · Steven R. Feldman · 2019 · 33 citations · Cited by this paper
  28. Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment · Sascha Gerdes · 2023 · 33 citations · Cited by this paper
  29. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial · Kexiang Yan · 2024 · 32 citations · Cited by this paper
  30. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis · Lin Cai · 2024 · 23 citations · Cited by this paper
  31. Vunakizumab: First Approval · Susan J. Keam · 2024 · 22 citations · Cited by this paper
  32. Patient-reported outcomes in psoriasis research and practice · Michel Fleith Otuki · 2011 · 20 citations · Cited by this paper
  33. Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review · Dahyeon Kim · 2025 · 20 citations · Cited by this paper
  34. Durability and long-term outcomes of biologic therapies in psoriasis · Lluís Rusiñol · 2023 · 17 citations · Cited by this paper
  35. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch · Veronique Gaudet · 2023 · 9 citations · Cited by this paper
  36. Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab · Xing‐Hua Gao · 2024 · 8 citations · Cited by this paper
  37. Efficacy and safety of secukinumab in psoriasis: five-year real life experience · Ersoy Acer · 2024 · 4 citations · Cited by this paper
  38. Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial · Lin Bo Cai · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)